Immunohistochemical expression of clusterin in colorectal carcinoma

Jalal Ali Jalal; Zheen Othman; Payman Anwar

doi:10.15218/zjms.2021.018

Authors

Jalal Ali Jalal Department of Basic Sciences, College of Medicine, Hawler Medical University, Erbil, Iraq
Zheen Othman Department of Basic Sciences, College of Medicine, Hawler Medical University, Erbil, Iraq
Payman Anwar Department of Basic Sciences, College of Medicine, Hawler Medical University, Erbil, Iraq

DOI:

https://doi.org/10.15218/zjms.2021.018

Keywords:

Colorectal cancer, Clusterin, Immunohistochemistry

Abstract

Background and objective: Colorectal cancer is a heterogeneous malignancy characterized by a wide range of genetic and epigenetic alterations. Clusterin is a heterodimeric glycoprotein widely expressed in a variety of tissues and secreted in many body fluids. Increased clusterin expression has been reported in the normal colonic mucosa, benign polyps, and colorectal carcinoma. This study aimed to detect the frequency of the clusterin immunoexpression in colorectal carcinoma and determine its association with some clinicopathological parameters.

Methods: Sixty formalin-fixed paraffin-embedded sections of colorectal adenocarcinoma were obtained and randomly selected from the histopathology laboratory at Rizgary Teaching Hospital and some private histopathology laboratories in Erbil city over two years between December 2016 and December 2018. All patients had been diagnosed to have primary colorectal adenocarcinoma and had undergone surgery. The clinicopathological characteristics of the tumors were revised, and the specimens were analyzed immunohistochemically using anticlusterin mouse monoclonal antibody.

Results: Twenty eight cases (46.6%) were labeled as clusterin positive, while 32 cases (53.4%) were negative for clusterin expression. Clusterin expression was significantly associated with the tumor type (Non-mucinous) (P = 0.01) and tumor grade (well to moderately differentiated) (P = 0.03). At the same time, no significant association was found between clusterin immunoexpression and other clinicopathological characteristics like age, gender, tumor site, and tumor stage.

Conclusion: Our study indicated that clusterin is overexpressed in some colorectal carcinomas and is significantly associated with histological type and grade. These results suggest that clusterin may play a role in colorectal carcinogenesis. Further studies are required to understand the possible mechanism of clusterin association with carcinogenesis and cancer progression.

Metrics

Metrics Loading ...

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin2018; 68 (6):394–424.

Results of Iraqi Cancer Registry (1999-2004), Ministry of health, Iraq Cancer Registry Centre, Baghdad – Iraq; 2008.

Othman RT, Abdulljabar R, Saeed A, Kittani SS, Sulaiman HM, Mohammed SA, et al. Cancer incidence rates in the Kurdistan region/Iraq from 2007-2009. Asian Pac J Cancer Prev 2011; 12(5):1261–4.

Dan Li. Recent advances in colorectal cancer screening. Chronic Dis Transl Med 2018; 4(3):139–47.

Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncol Lett 2018; 16(1):9–18.

Inamura K. Colorectal Cancers: An Update on Their Molecular Pathology. Cancers (Basel) 2018; 10(1):26.

Zhang J, Miao C, Xu A, Zhao K, Qin Z, Li X, et al. Prognostic roleof secretory clusterin in multiple human malignant neoplasms: A meta analysis of 26 immunohistochemistry studies. PLoS One 2016; 11(8):e0161150.

Andersen CL, Schepeler T, Thorsen K, Demtroder KB, Mansilla F, Aaltonen LA, et al. Clusterin expression in normal mucosa and colorectal cancer. Mol Cell Proteomics 2007; 6(6):1039–48.

Trougakos IP, Djeu JY, Gonos ES, Boothman DA. Advances and challenges in basic and translational research on clusterin. Cancer Res 2009; 69(2):403–6.

Pucci S, Bonanno E, Sesti F, Mazzarelli P, Mauriello A, Ricci F, et al.Clusterin in stool: A new biomarker for colon cancer screening. Am J Gastroenterol 2009; 104(11):2807–15.

Koltai T. Clusterin: a key player in cancer chemoresistance and its inhibition. Onco Targets Ther 2014; (7):447–56.

Xie D, Sham JST, Zeng WF, Che LH, Zhang M, Wu HX, et al. Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. World J Gastroenterol 2005; 11(21):3285–9.

Lore JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation proﬁles and consensus molecular subtypes. Clin Cancer Res 2017; 24(5):1062–72.

Bosman F.T, Carneiro F, Hruban R.H, Theise N.D. Tumors of the colon and rectum. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. 4thed. Lyon, France: IARC Press; 2010. P. 131–83.

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. Colon and Rectum. In: Jessup JM, Richard MG, Elliot AA, AB Benson III, James DB, George JC, eds. AJCC Cancer Staging Manual. 8th ed. Chicago: Springer Nuture; 2017. P. 251–74.

Gikas PD, Komborozos VA, Petraki CD, Morris T, Gikas DP. Utility of clusterin as a biomarker in human colorectal neoplasia. Hellenic J Surg 2012; 84(3):150–9.

Kevans D, Foley J, Tenniswood M, Sheahan K, Hyland J, Donoghue DO, et al. High clusterin expression correlates with a poor outcome in stage II colorectal cancers. Cancer Epidemiol Biomarkers Prev 2009; 18(2):393–9.

Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. Prognostic and predictive response factors in colorectal cancer patients. World J Gastroenterol 2014; 20(41):15049–59.

Rodrı AM, Cadena MP, Saco AP, Berrocal FJ. Differential expression of serum clusterin isoforms in colorectal cancer. Mol Cell Proteomics 2006; 5(9):1647–57.

Redondo M, Rodrigo I, Alcaide J, Tellez T, Roldan MJ, Funez R, et al. Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas. Histopathology 2010; 56(7):932–6.

Gomaa W, Al-ahwal M, Al-maghrabi H, Buhmeida A, Al-qahtani, Al-maghrabi BM, et al. Expression of clusterin in colorectal carcinoma in relation to clinicopathological criteria. Malaysian J Pathol 2017; 39(3):243–50.

Ali AJ, Al-Ogaili AA, Salih HI. Comparison of colorectal cancer in patients below and above 40 years. Iraqi J Comm Med 2017; 30:1:38–43.

Mahmood KI, Namiq KF, Muhamad CA, Muhamad BO, Majed KM, Fattah HN. A descriptive study of colorectal cancer in Hiwa cancer hospital, Sulaymaniyah, Iraq. Science Journal of University of Zakho 2017; 5(3):244–8.

AlrubaieA, Alkhalidi N, Abdl-husain S. A clinical study of newly-diagnosed colorectal cancer over 2 years in a gastroenterology center in Iraq. Journal of Coloroctology 2019; 39:(3):217–22.

Artemaki PI, Sklirou AD, Kontos CK, Liosi AA, Gianniou DD, Papadopoulos IN, et al. High clusterin (CLU) mRNA expression levels in tumors of colorectal cancer patients predict a poor prognostic outcome. Clin Biochem 2019; 75(2020):62–9.

Purim O, Gordon N, Brenner B. Cancer of the colon and rectum: Potential effects of sex-age interactions on incidence and outcome. Med Sci Monit 2013; 19:203–9.

Hugen NC, Velde JH, Wilt HW, Nagtegaal D. Metastatic pattern in colorectal cancer is strongly inﬂuenced by histological subtype. Ann Oncol 2014; 25:651–7.

Razenberg LGEM, Gestel YRBM, Lemmens VEPP, de Wilt JHWD, Creemers GJ, de Hing IHJT. The prognostic relevance of histological subtype in patients with peritoneal metastases from colorectal cancer: a nationwide population-based study. Clin Colorectal Cancer 2015; 14(4):13–9.

Jin J, Kim JM, Hur YS, Cho WP, Lee KY, Ahn SI, et al. Clinical significance of clusterin immunoexpression in pancreatic adenocarcinoma. World J Surg Oncol 2012; 10:146.

Yang GF, Li XM, Xie D. Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 2009; 19(8):1342–6.